Dhiman, Kunal

Gupta, Veer Bala

Villemagne, Victor L

Eratne, Dhamidhu

Graham, Petra L

Fowler, Christopher

Bourgeat, Pierrick

Li, Qiao-Xin

Collins, Steven

Bush, Ashley I

Rowe, Christopher C

Masters, Colin L

Ames, David

Hone, Eugene

Blennow, Kaj

Zetterberg, Henrik

Martins, Ralph N

2020-02-27

This study assessed the utility of cerebrospinal fluid (CSF) neurofilament light (NfL) in Alzheimer's disease (AD) diagnosis, its association with amyloid and tau pathology, as well as its potential to predict brain atrophy, cognition, and amyloid accumulation. CSF NfL concentration was measured in 221 participants from the Australian Imaging, Biomarkers & Lifestyle Flagship Study of Ageing (AIBL). CSF NfL levels as well as NfL/amyloid β (Aβ42) were significantly elevated in AD compared to healthy controls (HC; P < .001), and in mild cognitive impairment (MCI) compared to HC (P = .008 NfL; P < .001 NfL/Aβ42). CSF NfL and NfL/Aβ42 differentiated AD from HC with an area under the receiver operating characteristic (ROC) curve (AUC) of 0.84 and 0.90, respectively. CSF NfL and NfL/Aβ42 predicted cortical amyloid load, brain atrophy, and cognition. CSF NfL is a biomarker of neurodegeneration, correlating with cognitive impairment and brain neuropathology.

Alzheimer's & dementia (Amsterdam, Netherlands) 2020; 12(1): e12005

2352-8729

Alzheimer's & dementia (Amsterdam, Netherlands)

0000-0002-5832-9875

https://ahro.austin.org.au/austinjspui/handle/1/22882

ELISA

amyloid

biomarker

dementia

diagnosis

neurodegeneration

neurofilaments

Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease.

Journal Article